NEW YORK, Nov. 11, 2013 /PRNewswire/ -- Morgan & Morgan announces that it is investigating potential legal claims against the board of directors of Santarus, Inc. ("Santarus" or the "Company") (NASDAQ: SNTS) concerning the proposed acquisition of the Company by Salix Pharmaceuticals, Ltd. ("Salix").
Under the terms of the proposed transaction, Santarus stockholders will receive $32.00 in cash for each share of Santarus owned, valuing the transaction at approximately $2.6 billion.
If you own shares of Santarus and want more information about the Santarus takeover investigation please contact George Pressly, Esq. at 1(800) 631-6234 or email George at AskGeorge@morgansecuritieslaw.com.
Our investigation concerns possible breaches of fiduciary duty and other violations of law by Santarus' Board of Directors for not acting in the best interest of the Company's shareholders in connection with the sale process.Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability. All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." Attorney advertising. Prior results do not guarantee a similar outcome. Contact:Morgan & Morgan Peter Safirstein, Esq.28 West 44 th StreetSuite 2001 New York, NY 100361-800-631-6234 firstname.lastname@example.org SOURCE Morgan & Morgan